Orthobiologics Market Analysis, Size, Trends | China | 2020-2026 | MedSuite
- Year: 2020
- Scope: 2016-2026
- Region: China
- Pages: 131
- Published Date: 02/20/2020
- Type: MedSuite
By 2020, the Chinese orthobiologics market size was valued at $460.7 million, with over 424,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 6% to reach $690.8 million in 2026.
Throughout this medical market research, we analyzed 28 orthobiologics companies across China and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.
While this MedSuite report contains all of the Chinese Orthopedic Biomaterials market data and analysis, each of the market segments is also available as stand-alone MedCore reports. This allows you to get access to only the market research that you need.
DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Orthobiologics Procedure Volumes
- Market Forecasts Until 2026, and Historical Data to 2016
- Competitive Analysis with Market Shares for Each Segment
- Market Drivers & Limiters for Each Orthopedic Biomaterials Device market
- Recent Mergers & Acquisitions
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
Market Value and Industry Trends
Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, approximately 12% of the Chinese population was aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.
In the past, lower-tier hospitals (I and II) were primarily served by local manufacturers with relatively simple products at significantly lower prices than the products purchased by tier III hospitals, which were primarily supplied by international companies. Now, with the financial and regulatory support of the government, increasingly difficult entry barriers for international products and weak intellectual property protection that incentivizes product plagiarism, the market has shifted in favor of local manufacturers.
Competitive Analysis
By 2020, the leading competitor in the Chinese orthopedic biomaterials market was Kunming Baker Norton, which was attributed to its leading position in the HA viscosupplementation market. Kunming Baker Norton’s portfolio includes the five-injection ARTZ® product line, which is originally manufactured by Seikagaku.
Haohai Biologic Technology was the second-leading competitor in the Chinese market. The company held the second-leading position in the three-injection HA viscosupplementation market and the third-leading position in the five-injection HA viscosupplementation market.
Segments Covered
Click on each title to view more detailed market segmentation.
- Procedure Volumes for Orthopedic Biomaterials Devices – MedPro – The Complete procedural analysis for each segment of the Chinese Orthopedic Biomaterials market.
- Orthopedic Bone Graft Substitute Market – MedCore – This market is further segmented by Material Type, including Allograft, Demineralized Bone Matrix Allograft, and Synthetic. Each of these Material Types is segmented by Spine, Trauma, Large Joint Reconstruction, Craniomaxillofacial, and Oncology.
- Orthopedic Growth Factor Market – MedCore – In-depth analysis of the Orthopedic Growth Factor market.
- Hyaluronic Acid Viscosupplementation Market – MedCore – This market is categorized by Treatment Type, including Three-Injection and Five-Injection.
Detailed Market Segmentation
DON’T SEE THE SEGMENT OR DATA YOU NEED?
Feel free to contact us or send a request by pressing one of the buttons below.
TABLE OF CONTENTS FOR THE CHINESE ORTHOPEDIC BIOMATERIALS MARKET REPORT SUITE
TABLE OF CONTENTS ILIST OF FIGURES VIIILIST OF CHARTS XVEXECUTIVE SUMMARY 1CHINESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1COMPETITIVE ANALYSIS 3MARKET TRENDS 5MARKET DEVELOPMENTS 6PROCEDURE NUMBERS 7MARKETS INCLUDED 8KEY REPORT UPDATES 10VERSION HISTORY 10RESEARCH METHODOLOGY 11Step 1: Project Initiation & Team Selection 11Step 2: Prepare Data Systems and Perform Secondary Research 14Step 3: Preparation for Interviews & Questionnaire Design 16Step 4: Performing Primary Research 17Step 5: Research Analysis: Establishing Baseline Estimates 19Step 6: Market Forecast and Analysis 20Step 7: Identify Strategic Opportunities 22Step 8: Final Review and Market Release 23Step 9: Customer Feedback and Market Monitoring 24PRODUCT ASSESSMENT
2.1 INTRODUCTION 252.2 PRODUCT PORTFOLIOS 252.2.1 Bone Graft Substitutes 262.2.2 Growth Factors 322.2.2.1 Other Products 352.2.3 Hyaluronic Acid Viscosupplementation (HAV) 372.3 REGULATORY ISSUES AND RECALLS 402.3.1 Bone Graft Substitutes 402.3.1.1 Allografts 402.3.1.1.1 MTF 402.3.1.2 DBM 402.3.1.2.1 AlloSource 402.3.1.2.2 SeaSpine 412.3.1.2.3 RTI Surgical 412.3.1.3 Synthetics 412.3.1.3.1 Abyrx 412.3.1.3.2 Zimmer Biomet 422.3.2 Growth Factors 422.3.2.1.1 Medtronic 422.3.3 Hyaluronic Acid Viscosupplementation 432.3.3.1 Three-injection 432.3.3.1.1 Ferring Pharmaceuticals 432.4 CLINICAL TRIALS 442.4.1 Bone Graft Substitutes 442.4.1.1 Allografts 442.4.1.1.1 Providence Medical Technology 442.4.1.1.2 The University of Texas Health Science 442.4.1.1.3 University of Winchester 452.4.1.2 BDM 452.4.1.2.1 K2M 452.4.1.2.2 Zimmer Biomet 462.4.1.3 Synthetics 462.4.1.3.1 Baxter 462.4.1.3.2 Bonesupport 472.4.1.3.3 DePuy Synthes 472.4.1.3.4 NuVasive 492.4.1.3.5 RTI surgical 492.4.1.3.6 Sunstar GUIDOR 502.4.1.4 Other materials and comparison 512.4.1.4.1 Seoul National University Hospital. 512.4.1.4.2 Sewon Cellontech 512.4.1.4.3 SurgaColl Technologies Limited 522.4.1.4.4 University of Colorado 522.4.1.4.5 University of Padova 532.4.2 Growth Factors 532.4.2.1.1 Bioventus 532.4.2.1.2 Cerapedics 542.4.2.1.3 CGBio 542.4.2.1.4 Isto 552.4.2.1.5 Medtronic 552.4.2.1.6 NuVasive 572.4.2.1.7 Wright 572.4.2.1.8 Others 582.4.3 Hyaluronic Acid Viscosupplementation 592.4.3.1.1 Anika Therapeutics 592.4.3.1.2 Bioventus 602.4.3.1.3 Cairo University 612.4.3.1.4 Ferring Pharmaceuticals 612.4.3.1.5 Federal University of Minas Gerais 622.4.3.1.6 Fidia Pharma USA Inc. 622.4.3.1.7 Istituto Ortopedico Rizzoli 632.4.3.1.8 University Hospital 632.4.3.1.9 Universidade Nova de Lisboa 64CHINA ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
3.1 INTRODUCTION 653.1.1 Bone Graft Substitutes 653.1.2 Growth Factors 653.1.3 Hyaluronic Acid (HA) Viscosupplementation 663.2 CURRENCY EXCHANGE RATE 673.3 MARKET OVERVIEW AND TREND ANALYSIS 683.4 DRIVERS AND LIMITERS 763.4.1 Market Drivers 763.4.2 Market Limiters 763.5 COMPETITIVE MARKET SHARE ANALYSIS 783.6 MERGERS AND ACQUISITIONS 843.7 COMPANY PROFILES 863.7.1 Anika Therapeutics 863.7.2 Bioventus 873.7.3 DePuy Synthes 883.7.4 Ferring Pharmaceuticals 893.7.5 Fidia Pharmaceuticals 903.7.6 Genzyme (Sanofi Group) 913.7.7 Harvest Technologies (Terumo BCT) 923.7.8 Integra LifeSciences 933.7.9 Medtronic 943.7.10 Musculoskeletal Transplant Foundation (MTF) 963.7.11 NuVasive 973.7.12 Orthofix 983.7.13 RTI Surgical 993.7.14 Stryker 1003.7.15 Vericel Corporation (formerly Aastrom Bioscience) 1013.7.16 Zimmer Biomet 1023.8 SWOT ANALYSIS 1043.8.1 Anika Therapeutics 1043.8.2 Bioventus 1063.8.3 DePuy Synthes 1083.8.4 Ferring Pharmaceuticals 1093.8.5 Fidia Pharmaceuticals 1103.8.7 Harvest Technologies (Terumo BCT) 1123.8.8 Integra LifeSciences 1133.8.9 Medtronic 1143.8.10 Musculoskeletal Transplant Foundation (MTF) 1153.8.11 NuVasive 1163.8.12 Orthofix 1173.8.14 Stryker 1193.8.15 Vericel Corporation (formerly Aastrom Bioscience) 1203.8.16 Zimmer Biomet 121PROCEDURE NUMBERS
4.1 INTRODUCTION 1234.2 PROCEDURES 1244.2.1 Orthopedic Biomaterial Procedures by Segment 1244.2.2 Orthopedic Bone Grafting Procedures 1264.2.2.1 Units per Procedure by Indication 1264.2.2.2 Orthopedic Bone Grafting Procedures by Material 1274.2.2.2.1 Autograft Procedures by Indication 1294.2.2.2.2 Allograft Procedures by Indication 1324.2.2.2.3 DBM Procedures by Indication 1354.2.2.2.4 Synthetic Procedures by Indication 1384.2.2.3 Orthopedic Bone Grafting Procedures by Indication 1414.2.3 Orthopedic Growth Factor Procedures 1444.2.4 Hyaluronic Acid Supplementation Procedures 1464.2.4.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle 146ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET
5.1 INTRODUCTION 1485.2 MARKET OVERVIEW 1495.2.1 Orthopedic Bone Graft Substitute Market by Material 1495.2.2 Orthopedic Bone Graft Substitute Market by Indication 1555.3 MARKET ANALYSIS AND FORECAST 1615.3.1 Total Orthopedic Bone Graft Substitute Market 1615.3.2 Orthopedic Bone Graft Substitute Market by Material 1635.3.2.1 Allograft Bone Graft Substitute Market 1635.3.2.1.1 Allograft Bone Graft Substitute Market by Indication 1655.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 1795.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication 1815.3.2.3 Synthetic Bone Graft Substitute Market 1955.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication 1975.3.3 Orthopedic Bone Graft Substitute Market by Indication 2115.3.3.1 Spine Bone Graft Substitute Market 2115.3.3.2 Cervical Spine Bone Graft Substitute Market 2135.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market 2155.3.3.4 Trauma Bone Graft Substitute Market 2175.3.3.5 Non-Union Trauma Bone Graft Substitute Market 2195.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market 2215.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market 2235.3.3.8 Hip Reconstruction Bone Graft Substitute Market 2255.3.3.9 Knee Reconstruction Bone Graft Substitute Market 2275.3.3.10 Foot Reconstruction Bone Graft Substitute Market 2295.3.3.11 Craniomaxillofacial Bone Graft Substitute Market 2315.3.3.12 Oncology Bone Graft Substitute Market 2335.4 DRIVERS AND LIMITERS 2355.4.1 Market Drivers 2355.4.2 Market Limiters 2355.5 COMPETITIVE MARKET SHARE ANALYSIS 237ORTHOPEDIC GROWTH FACTOR MARKET
6.1 INTRODUCTION 2416.2 MARKET ANALYSIS AND FORECAST 2426.3 DRIVERS AND LIMITERS 2446.3.1 Market Drivers 2446.3.2 Market Limiters 2446.4 COMPETITIVE MARKET SHARE ANALYSIS 246HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
7.1 INTRODUCTION 2477.1.1 Benefits of Viscosupplementation 2487.1.2 Synovial Fluid 2487.2 MARKET OVERVIEW 2497.3 MARKET ANALYSIS AND FORECAST 2557.3.1 Total Hyaluronic Acid Viscosupplementation Market 2557.3.2 Three-Injection Hyaluronic Acid Viscosupplementation Market 2577.3.3 Five-Injection Hyaluronic Acid Viscosupplementation Market 2597.4 DRIVERS AND LIMITERS 2617.4.1 Market Drivers 2617.4.2 Market Limiters 2617.5 COMPETITIVE MARKET SHARE ANALYSIS 263ABBREVIATIONS
|
|